No association between use of angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID‐19 in the COvid MEdicaTion (COMET) study

Since the outbreak of SARS‐CoV‐2, also known as COVID‐19, conflicting theories have circulated on the influence of angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) on incidence and clinical course of COVID‐19, but data are scarce. The COvid MEdicaTion (COMET...

Descripción completa

Detalles Bibliográficos
Autores principales: Sablerolles, Roos S. G., Hogenhuis, Freija E. F., Lafeber, Melvin, van de Loo, Bob P. A., Borgsteede, Sander D., Boersma, Eric, Versmissen, Jorie, van der Kuy, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014637/
https://www.ncbi.nlm.nih.gov/pubmed/33507556
http://dx.doi.org/10.1111/bcp.14751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014637/
https://www.ncbi.nlm.nih.gov/pubmed/33507556
http://dx.doi.org/10.1111/bcp.14751

Ejemplares similares